ResMed Inc. vs Vistra Corp — how do they compare? ResMed Inc. trades at $229.95 (market cap $31.89B), while Vistra Corp trades at $157.09 (market cap $52.41B). The key difference: Vistra Corp is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vistra Corp for 32 Days on average.
| RMD | VST | |
|---|---|---|
Market Cap | $31.89B | $52.41B |
Volume | 618,314 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $277.88 | $210.85 |
52-Week Low | $182.82 | $134.71 |
Typical Hold Time | 51 Days | 32 Days |
Enterprise Value | $31.24B | $74.34B |
Dividend Yield | 1.16% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Vistra Corp (VST) trades at $166.72, up 3.88% with strong analyst support (91% buy ratings) and a $215.23 consensus target. The stock shows bullish technical momentum above key support at $162, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra offers compelling exposure to the AI power infrastructure theme with strong profitability and government backing, though investors face earnings volatility risks as seen in recent quarterly misses. The stock trades at a premium valuation (P/E 26.33) but maintains upside potential if execution on nuclear expansion and data center contracts meets expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →